- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04414527
Effects of Video-based Health Education on Maternal and Child Health in Ethiopia (MCH)
Effects of Video-based Health Education on Health Status of Pregnant Mothers and Their Infants (From 0 to 6 Months) in Dirashe District Southern Ethiopia - a Cluster Randomized Controlled Trial.
Low adherence to recommended health and nutrition strategies during the critical 1000 day-window of opportunity is multifactorial but low quality communication is key limitation. Innovative strategies to improve interpersonal communication can reduce the burden and the fatigue of community health workers and may result in a greater change. The findings of this project will support governments and other stakeholders in their delivery of high impact nutrition and health practices.
This intervention aims to improve adherence to ante- and post-natal care practices and recommendations by the use of our video-based health education. These videos will be implemented through home-based counseling by trained assistants, and video-based forum participation led by community nurses and health extension workers (HEWs). During the monthly forums, the educational package will be delivered in a video form - locally prepared using multiple approaches like testimony, comedy, dramas in the form of questions and answers, group discussions and deductive approaches. Cordless projectors and locally created videos give the health community more quality control over the end message, expand the number of people reached, allow for the use of minimally trained non-expert facilitators such as the hews, and allow for contextually appropriate information. They can also be used in areas without access to electricity, helping to bridge the digital divide, and serving as a leapfrog technology for areas that would otherwise not have access to media.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In Ante- and post-natal care, low adherence to recommended health and nutrition strategies during the critical 1,000 day-window of opportunity is multifactorial, but low-quality communication is key limitation. Innovative strategies to improve interpersonal communication can reduce the burden and the fatigue of community health workers and may result in a greater change. The findings of this project will support governments and other stakeholders in their delivery of high impact nutrition and health practices.
Focused antenatal care (FANC), including iron and folic acid supplementation (IFA) is one of the main strategies to reduce maternal and child deaths. The WHO recommends at least four hospital visits during the pregnancy. Supplementation with IFA during pregnancy improves birth weight and reduces megaloblastic anemia by 79%. The uptake of nutritional and health practices is influenced by complex, contextual determinants at the individual and community levels. Evidence showed that Social and Behavior Change Communication (SBCC) is an effective approach to increase the uptake of key strategies and to sustain behavior change.
Ethiopia, a low-income country in sub-Saharan Africa, has one of the highest maternal and infant mortality rates. It is estimated that 676 mothers die per 100,000 live births and that 59 infants die per 1,000 live births. Maternal anemia is associated with an increased risk of maternal death. Iron deficiency anemia is a strong risk factor for low birthweight (LBW) and perinatal mortality. genital infections such as bacterial vaginosis, candidiasis and worm infections (such as intestinal hookworm infections) are considered important infections that possibly could confound the study results. Bacterial vaginosis and candidiasis are a known risk factor for preterm birth. these infections are also linked with anemia and maternal nutritional status. Hookworm infections are highly prevalent in Ethiopia and are associated with undernutrition and anemia.
The reports of the Ethiopian Demographic and Health Survey showed an increase in women aged 15-49 years in Ethiopia receiving antenatal care (ANC) from a skilled provider up to 62% in 2016 (EDHS, 2016). The percentage of women taking IFA supplements for 90 days or more remains at a substandard level of only 5% (EDHS, 2016). Antenatal care coverage for at least one visit is 28% but coverage for at least four visits declines to 12%, suggesting systemic barriers that potentially prevent the mothers from returning to the health centers. One of the barriers may be perceived failure of the existing interventions to make a meaningful impact that could stimulate the desired behavioral change.
This intervention aims to improve adherence to ante- and post-natal care practices and recommendations by the use of our video-based health education. These videos will be implemented through home-based counseling by trained assistants, and video-based forum participation led by community nurses and Health Extension Workers (HEWs). The nutrition-specific education packages will be based on the WHO-UNICEF key messages booklet on the community, infant and young child feeding counseling package and will be culturally adjusted to fit the local context and translated into the main four local languages. The videos will also include some hygienic aspects that reduce the risk of both genital and parasitic infections, that are also causing undernutrition, anemia and/or adverse pregnancy outcomes. During the monthly forums, the educational package will be delivered in a video form - locally prepared using multiple approaches like testimony, comedy, dramas in the form of questions and answers, group discussions and deductive approaches (more details can be found on OMPT website https://www.ompt.org/).
The main objective of this project is to assess the effects of this innovative video-based health education on reproductive health, and on birth outcomes and the nutritional status of women and their infants from birth to six months of age.
PRIMARY OBJECTIVES
- To assess the effects of video-based health education package provided to pregnant and lactating women on the knowledge, attitude and practice on recommended health including adherence to ANC visits and to IFA supplementation.
- To assess the effects of video-based health education on birth outcomes and anemia status of women during pregnancy, at delivery and six-month postpartum.
- To evaluate the effect of video-based health education on early initiation and exclusive breastfeeding (EBF) of infants from 0-6 months of age In this two-arm cluster randomized trial, 675 pregnant women in their first trimester (12 weeks of gestation) will be recruited and followed up until delivery and then with their infants for six months postpartum.
The intervention will include home to home visit for delivery of healthy nutrition and hygienic messages using prepared video-based messages. participation in monthly forums will be facilitated by nurses using also videos for demonstration of nutritional and hygienic care and will be delivered at the homes of the participants every month by trained HEW until delivery, in addition to the ANC regular visits. During the monthly forums (six in total during the pregnancy and the post-partum periods), the messages will all be given as a video show, coordinated by a nurse/ health professional who will further answer any questions. During the postnatal period, two counseling sessions will be organized within the first two weeks after birth, and a further six sessions ( every month) till 6 months postnatally.
The HEW will distribute the IFA 30 tablets (30 mg elemental iron and 400 µg of folic acid) every month, and will provide counseling on the importance of- and instructions on adherence and other recommendations as detailed earlier. Pregnant women in the control group will receive the standard education package as per the Ethiopian guidelines. In the standard health care, pregnant women receive a minimum of four ANC visits at the health centers during which they also receive IFA supplementation. The control and the intervention groups receive the same amount of tablets (i.e. 30 tablets containing 30 mg elemental iron and 400 µg of folic acid, every month). Monthly IFA utilization will be checked through HEW or our trained service delivery workers during home to home visit. Women who test positive for soil-transmitted helminth will be treated according to the national protocol starting from the second trimester (treatment is not advised during the first trimester). Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis.
Data will be collected in pregnant women at baseline, at six and at 9 months of pregnancy . After delivery data will be collected in the pairs mother-infant within two weeks and at 3 and 6 months postpartum. At the different time points, biological samples will be collected to assess the micronutrient status, the presence of inflammations and the presence of genital and parasitic infections.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Dirashe District
-
Arba Minch, Dirashe District, Ethiopia
- Arba Minch University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent form
- Aged at least 18 years
- Permanent resident of the village of the study intervention/control
- Planned availability during the whole period of the study (12 months)
- Acceptance of the intervention package including home visits for data collection and morbidity follow up.
Exclusion Criteria:
- Severe anemia (hemoglobin <70 g/L),
- Under nutrition (defined as body mass index before pregnancy of <18.5 kg/m2),
- Chronically ill mothers with tuberculosis or other chronic diseases,
- Reported HIV-positive mother.
- Individuals with anatomical deformity will be excluded due to the difficulty of measurement of height.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Standard counseling
Pregnant women in the control group will receive the standard education package as per the Ethiopian guidelines.
In the standard health care, pregnant women receive a minimum of four ante-natal care visits at the health centers during which they also receive iron and folic acid supplementation.
They participate in monthly forums facilitated by nurses to answer questions and concerns regarding nutritional care.
|
The control cohort will receive national standard counseling during four ante-natal care visits. Women in the control group will receive additionally
Other Names:
|
Experimental: Health-Video
Women in the Health-Video group will receive home visits for delivery of healthy nutrition messages using prepared video-based messages every two weeks.
They will also participate in monthly forums facilitated by nurses using also videos for demonstration of nutritional care.
During the monthly forums (six in total during the pregnancy and the post-partum periods), the messages will all be given as a video show coordinated by a nurse/ health professional for any questions.
During postnatal period, two counseling sessions will be delivered within two weeks of birth, and 12 sessions or twice every month till 6 months.
|
The intervention cohort Health-Video will receive innovative video-based nutritional and hygienic education. Women in this group will receive additionally:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to iron and folic acid supplementation during pregnancy
Time Frame: Monthly during six months pregnancy
|
Monthly disappearance rate of IFA tablets
|
Monthly during six months pregnancy
|
Adherence to iron and folic acid supplementation post-partum
Time Frame: Monthly during three months postpartum
|
Monthly disappearance rate of IFA tablets
|
Monthly during three months postpartum
|
Maternal anemia during pregnancy
Time Frame: Hemoglobin concentrations will be measured at 9 months pregnancy
|
Hemoglobin concentrations (g/dL)
|
Hemoglobin concentrations will be measured at 9 months pregnancy
|
Maternal anemia post-partum
Time Frame: Hemoglobin concentrations will be measured at six months postpartum
|
Hemoglobin concentrations (g/dL)
|
Hemoglobin concentrations will be measured at six months postpartum
|
Early initiation
Time Frame: At birth (six months after the enrollment)
|
Prevalence of newborns put to the breast in the first hour after birth
|
At birth (six months after the enrollment)
|
Exclusive breastfeeding
Time Frame: Birth to six months postpartum
|
Prevalence of infants exclusively breastfed using maternal reports and the deuterium dose-to-mother technique (in a subgroup)
|
Birth to six months postpartum
|
Dietary intake during six months pregnancy
Time Frame: Assessed at 6 months and 9 months pregnancy
|
Prevalence of women with adequate dietary intake during six months pregnancy
|
Assessed at 6 months and 9 months pregnancy
|
Dietary intake at six months post-partum
Time Frame: Assessed at six months postpartum
|
Prevalence of women with adequate dietary intake at six months post-partum
|
Assessed at six months postpartum
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gestational weight gain
Time Frame: Gestational weight gain will be measured in all pregnant women at six and nine months pregnancy
|
Weight gain at term (Kg)
|
Gestational weight gain will be measured in all pregnant women at six and nine months pregnancy
|
Maternal genital infections
Time Frame: Maternal genital infections will be assessed at nine months pregnancy
|
The presence of genital infections that are known to affect a healthy pregnancy, including but not limited to bacterial vaginosis, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Listeria monocytogenes.
|
Maternal genital infections will be assessed at nine months pregnancy
|
Birth weight
Time Frame: Birth weight will be assessed in all newborns
|
Birth weight (g)
|
Birth weight will be assessed in all newborns
|
Infant weight
Time Frame: Weight of infants will be assessed monthly from birth until six months of age
|
Infant weight (g) on a monthly basis
|
Weight of infants will be assessed monthly from birth until six months of age
|
Infant length
Time Frame: Length of infants will be assessed monthly from birth until six months of age
|
Infant length (cm) on a monthly basis
|
Length of infants will be assessed monthly from birth until six months of age
|
Infant anemia
Time Frame: Hemoglobin concentrations will be measured at six months of age
|
Hemoglobin concentrations (g/dL)
|
Hemoglobin concentrations will be measured at six months of age
|
Maternal parasitic infections
Time Frame: Worm infections will be assessed in all women at 6 months pregnancy, 9 months pregnancy, and at two weeks- and 6 months post partum
|
The presence of worm parasites and egg density in the stools.
Three common parasites and their eggs will be investigated, i.e.
Ascaris lumbricoides (round worm), Trichuris trichiura (whipworm) and Ancyclostoma duodenale or Necater americanus (hookworms).
|
Worm infections will be assessed in all women at 6 months pregnancy, 9 months pregnancy, and at two weeks- and 6 months post partum
|
Infant parasitic infections
Time Frame: Infant parasitic infections will be assessed at 6 months of age.
|
The prevalence of Giarida and Cryposporidium will be assessed in all infants
|
Infant parasitic infections will be assessed at 6 months of age.
|
Maternal plasma ferritin
Time Frame: Plasma ferritin is assessed in a subgroup of women at 9 months pregnancy and at six months postpartum
|
Iron status as indicated plasma ferritin (micro_g/L) is a test to evaluate iron stores
|
Plasma ferritin is assessed in a subgroup of women at 9 months pregnancy and at six months postpartum
|
Infant plasma ferritin
Time Frame: Plasma ferritin is assessed in a subgroup of infants at six months of age
|
Iron status as indicated plasma ferritin (micro_g/L) is a test to evaluate iron stores
|
Plasma ferritin is assessed in a subgroup of infants at six months of age
|
Maternal soluble transferrin receptor
Time Frame: Plasma ferritin is assessed in a subgroup of women at 9 months pregnancy and at six months postpartum
|
Soluble transferrin receptor (mg/L) is an indicator for iron deficiency especially in high inflammation settings
|
Plasma ferritin is assessed in a subgroup of women at 9 months pregnancy and at six months postpartum
|
Infant soluble transferrin receptor
Time Frame: Soluble transferrin receptor is assessed in a subgroup of infants at six months of age
|
Soluble transferrin receptor (mg/L) is an indicator for iron deficiency especially in high inflammation settings
|
Soluble transferrin receptor is assessed in a subgroup of infants at six months of age
|
Maternal serum concentrations in Vitamin A (retinol)
Time Frame: Serum concentrations in Vitamin A are assessed in a subgroup of women at 9 months pregnancy and at six months postpartum
|
Retinol concentrations in serum is an indicator of vitamin A status
|
Serum concentrations in Vitamin A are assessed in a subgroup of women at 9 months pregnancy and at six months postpartum
|
Infant serum concentrations in Vitamin A (retinol)
Time Frame: Serum concentrations in Vitamin A are assessed in a subgroup of infants at six months of age
|
Retinol concentrations in serum is an indicator of vitamin A status
|
Serum concentrations in Vitamin A are assessed in a subgroup of infants at six months of age
|
Maternal serum concentrations in vitamin B12
Time Frame: Vitamin B12 concentrations will be assessed in a subgroup of women at 9 months pregnancy and at six months postpartum
|
Serum concentrations in vitamin B12
|
Vitamin B12 concentrations will be assessed in a subgroup of women at 9 months pregnancy and at six months postpartum
|
Infant serum concentrations in vitamin B12
Time Frame: Vitamin B12 concentrations will be assessed in a subgroup of infants at six months of age
|
Serum concentrations in vitamin B12
|
Vitamin B12 concentrations will be assessed in a subgroup of infants at six months of age
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bruno Levecke, PhD, University of Ghent
Publications and helpful links
General Publications
- Lassi ZS, Salam RA, Haider BA, Bhutta ZA. Folic acid supplementation during pregnancy for maternal health and pregnancy outcomes. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD006896. doi: 10.1002/14651858.CD006896.pub2.
- Rasmussen KM, Stoltzfus RJ. New evidence that iron supplementation during pregnancy improves birth weight: new scientific questions. Am J Clin Nutr. 2003 Oct;78(4):673-4. doi: 10.1093/ajcn/78.4.673. No abstract available.
- Brooker S, Bethony J, Hotez PJ. Human hookworm infection in the 21st century. Adv Parasitol. 2004;58:197-288. doi: 10.1016/S0065-308X(04)58004-1.
- Prociv P, Luke RA. Evidence for larval hypobiosis in Australian strains of Ancylostoma duodenale. Trans R Soc Trop Med Hyg. 1995 Jul-Aug;89(4):379. doi: 10.1016/0035-9203(95)90016-0. No abstract available.
- Asundep NN, Jolly PE, Carson AP, Turpin CA, Zhang K, Wilson NO, Stiles JK, Tameru B. Effect of Malaria and Geohelminth Infection on Birth Outcomes in Kumasi, Ghana. Int J Trop Dis Health. 2014;4(5):582-594. doi: 10.9734/IJTDH/2014/7573.
- Kavle JA, Landry M. Addressing barriers to maternal nutrition in low- and middle-income countries: A review of the evidence and programme implications. Matern Child Nutr. 2018 Jan;14(1):e12508. doi: 10.1111/mcn.12508. Epub 2017 Aug 24.
- Verstraelen H, Delanghe J, Roelens K, Blot S, Claeys G, Temmerman M. Subclinical iron deficiency is a strong predictor of bacterial vaginosis in early pregnancy. BMC Infect Dis. 2005 Jul 6;5:55. doi: 10.1186/1471-2334-5-55.
- Tuddenham S, Ghanem KG, Caulfield LE, Rovner AJ, Robinson C, Shivakoti R, Miller R, Burke A, Murphy C, Ravel J, Brotman RM. Associations between dietary micronutrient intake and molecular-Bacterial Vaginosis. Reprod Health. 2019 Oct 22;16(1):151. doi: 10.1186/s12978-019-0814-6.
- Ashorn P, Hallamaa L, Allen LH, Ashorn U, Chandrasiri U, Deitchler M, Doyle R, Harjunmaa U, Jorgensen JM, Kamiza S, Klein N, Maleta K, Nkhoma M, Oaks BM, Poelman B, Rogerson SJ, Stewart CP, Zeilani M, Dewey KG. Co-causation of reduced newborn size by maternal undernutrition, infections, and inflammation. Matern Child Nutr. 2018 Jul;14(3):e12585. doi: 10.1111/mcn.12585. Epub 2018 Jan 8.
- Bhutta ZA, Das JK, Rizvi A, Gaffey MF, Walker N, Horton S, Webb P, Lartey A, Black RE; Lancet Nutrition Interventions Review Group, the Maternal and Child Nutrition Study Group. Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost? Lancet. 2013 Aug 3;382(9890):452-477. doi: 10.1016/S0140-6736(13)60996-4. Epub 2013 Jun 6. Erratum In: Lancet. 2013 Aug 3;382(9890):396.
Helpful Links
- Review of Incorporation of Essential Nutrition Actions in Public Health Programs in Ethiopia. Washington, DC: Food and Nutrition Technical Assistance Project (FANTA)
- Evidence of Effective Approaches to Social and Behavior Change Communication for Preventing and Reducing Stunting and Anemia: Report from a Systematic Literature Review
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BC-06756
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
All the data that can affect the main or the secondary outcomes will be used in the analyses and shared as necessary.
Data on helminthic infection will use household characteristics and women and infants nutritional status
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on Standard counselling
-
University of AlbertaDanone Institute InternationalCompleted
-
Active Natural LimitedNMP Medical Research InstituteCompletedPost Traumatic Stress Disorder | Intimate Partner ViolenceIndia
-
University of New MexicoCompletedPatient Satisfaction | Fecal Incontinence | CounsellingUnited States
-
Mayo ClinicCompleted
-
Universita di VeronaCompleted
-
Unity Health TorontoActive, not recruiting
-
Fondazione Don Carlo Gnocchi OnlusRecruitingCardiovascular Diseases | Overweight and Obesity | Diabete Type 2Italy
-
University of Southern DenmarkDanish Cancer Society; National Board of Health, DenmarkUnknownSmoking | Smoking Cessation | Self-efficacyDenmark
-
Pavol Jozef Safarik UniversityUniversity of GroningenWithdrawnCardiovascular DiseasesSlovakia
-
Uppsala UniversityUniversity of Melbourne; Mid Sweden UniversityCompleted